The development of ACPA and rheumatoid factor autoantibodies precede disease development and expansion of ACPA and rheumatoid factor specific plasmablasts in RA patients with significant levels of somatic mutation, further indicating dysregulation in B cell maturation (4). Here, PRTN3 is linked to rheumatoid arthritis.